Roche signs drug discovery deal with Atavistik Bio worth up to $2 billion

On September 24, 2026, Swiss drugmaker Roche and biotech Atavistik Bio announced a strategic drug discovery partnership potentially worth up to $2 billion. Roche will pay $70 million upfront, with Atavistik eligible for up to $1.9 billion in milestones. The collaboration leverages Atavistik's AMPS platform to target hard-to-modulate proteins in cardiovascular, renal, and metabolic diseases, aligning with Roche's aggressive expansion in the cardiometabolic space.

Partnership roles and technology

• ▪Atavistik Bio signed a strategic research collaboration agreement with Swiss drugmaker Roche on September 24, 2026, to discover and develop novel oral small-molecule therapeutics.
• ▪Under the partnership, Atavistik Bio will lead early discovery and research activities, while Roche will handle preclinical and clinical development, regulatory filings, and commercialization.
• ▪The collaboration will utilize Atavistik Bio's proprietary AMPS allosteric drug discovery platform to identify novel functional binding pockets on historically hard-to-modulate disease-causing proteins.

Therapeutic targets and goals

• ▪The collaboration targets the development of oral small-molecule therapeutics for multiple undisclosed cardiovascular, renal, and metabolic disease targets.
• ▪The partnership aims to develop treatments that can be used as monotherapies or in combination with existing therapies to improve patient outcomes with fewer unintended side effects.

Financial terms of the agreement

• ▪Atavistik Bio is eligible to receive up to $1.9 billion in research, development, and commercial milestone payments, plus tiered royalties on future sales of approved drugs.
• ▪Roche will pay Atavistik Bio $70 million upfront as part of the agreement signed on September 24, 2026.

Roche's expansion in cardiometabolic diseases

• ▪Roche opened a new research and development center in Boston through its subsidiary Genentech on September 17, 2026, focused exclusively on cardiovascular, renal, and metabolic diseases.
• ▪Roche's strategic expansion in cardiometabolic diseases includes its 2023 acquisition of Carmot Therapeutics for $2.7 billion and its 2025 acquisition of MASH-focused 89bio for up to $3.5 billion.

Atavistik Bio's internal pipeline

• ▪Atavistik Bio will continue to independently develop its own internal pipeline of treatments for rare hematology diseases, including its lead asset ATV-1601 for hereditary hemorrhagic telangiectasia.
• ▪Atavistik Bio's investigational oral allosteric AKT1-selective inhibitor, ATV-1601, is currently being assessed in a Phase 1/2 clinical trial.

Debatable claims

• ▪Allosteric drug discovery platforms are reliable enough to justify multi-billion dollar pharmaceutical investments
• ▪Roche should rely on biotech partnerships for early-stage drug discovery rather than internal development
• ▪Milestone-heavy 'biobucks' contracts unfairly shift financial risk from major pharma to biotech startups
• ▪Oral small-molecule drugs are superior to injectable biologics for treating cardiometabolic diseases